Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

St Jude begins US trial for HF (heart failure) stimulation device:

This article was originally published in Clinica

Executive Summary

St Jude Medical has begun the US portion of its clinical trial to assess its Genesis biventricular resynchronisation device as a treatment for heart failure (HF). The VecToR (Ventricular Resynchronization Therapy Randomized) trial will evaluate low-voltage biventricular stimulation versus no stimulation therapy and will collect and assess data on more than 420 HF patients from around 40 centres worldwide, said the St Paul, Minnesota company. The Genesis system consists of three components - the Frontier 3x2 stimulation device, the Aescula LV left-heart lead and a catheter delivery system.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT074962

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel